Rajabally Y A
Neuromuscular Clinic, Department of Neurology, University Hospitals of Leicester, Leicester General Hospital, Leicester LE5 4PW, UK.
Postgrad Med J. 2008 Jun;84(992):287-92. doi: 10.1136/pgmj.2007.066209.
Initially described only about 20 years ago, multifocal motor neuropathy (MMN) is a predominantly distal, mainly upper limb, asymmetrical, pure motor neuropathy. MMN is immune mediated, and frequently associated with antiganglioside antibodies to GM1 of IgM type. The hallmark of MMN is the presence of conduction block (CB) on motor nerve conduction studies. There are, however, forms of MMN where CBs are not present or cannot be detected with routinely available diagnostic techniques. MMN is a treatable disorder, with about 80% of patients responding to intravenous immunoglobulins. For that reason, it needs to be distinguished from motor neuron disease, which is much more common but remains untreatable. MMN also needs to be distinguished from other immune mediated neuropathies as it is unresponsive to plasma exchanges and steroids, which may both cause it to deteriorate. As treatment is less effective later in the course of MMN, early recognition is vital. Long term management is, however, frequently complicated by progressive axonal degeneration resulting in functional decline despite treatment.
多灶性运动神经病(MMN)大约在20年前才首次被描述,它是一种以远端为主、主要累及上肢、不对称的纯运动性神经病。MMN是免疫介导的,常与IgM型抗GM1神经节苷脂抗体相关。MMN的标志是运动神经传导研究中存在传导阻滞(CB)。然而,存在一些MMN形式,其中不存在CB或无法用常规可用的诊断技术检测到CB。MMN是一种可治疗的疾病,约80%的患者对静脉注射免疫球蛋白有反应。因此,它需要与运动神经元病相鉴别,运动神经元病更为常见但仍无法治疗。MMN还需要与其他免疫介导的神经病相鉴别,因为它对血浆置换和类固醇无反应,而这两者都可能导致其病情恶化。由于MMN病程后期治疗效果较差,早期识别至关重要。然而,长期管理常常因进行性轴突变性而复杂化,尽管进行了治疗,但仍会导致功能下降。